Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Reports Slight Revenue Increase, Narrowing Losses

NEW YORK, Feb. 26 (GenomeWeb News) - Orchid BioSciences recorded slightly increased revenues and narrowing losses for the fourth quarter of 2003, the company said today.

 

Revenues were $13.7 million, up from $13 million during the same period a year ago.

 

R&D costs decreased sharply, to $0.2 million, from $3 million during the fourth quarter of 2002. This is primarily a result of Orchid's divesture of its SNP genotyping instrumentation business, and of strategic changes of its GeneShield business, according to the company.

 

The company's net loss amounted to $7.3 million, or $.09 per share, down from $35.1 million, or $.63 per share, during the year-ago period.

 

As of Dec. 31, Orchid had $9.9 million in cash and cash equivalents.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.